Introduction {#Sec1}
============

Bipolar disorder (BD) is a severe neuropsychiatric disorder, affecting approximately 1--2% of the population (Merikangas et al. [@CR45]). Mania is the cardinal feature of BD and traditionally has been assessed using self- and observer-rating scales. The qualitative nature of rating scales may contribute to the paucity of animal models for BD mania with most models being based on simple measures of motoric hyperactivity (Einat [@CR12]).

Motoric hyperactivity can be induced in rodents by manipulating numerous disparate neurotransmitter systems, yet these stimulants can be distinguished from one another by their differential effects on patterns of exploratory and locomotor behavior (Eilam and Golani [@CR10]; File and Wardill [@CR13]; Geyer [@CR18]; Geyer and Paulus [@CR20]; Geyer et al. [@CR21]; Paulus and Geyer [@CR50]; Szechtman et al. [@CR64]). Traditionally, quantitative assessments of activity, exploration, and locomotor patterns have required the use of different testing chambers, such as the open field test, photobeam activity chambers, and holeboard tasks (Bushnell [@CR3]; Collins et al. [@CR7]; Fink and Smith [@CR14]; Fitzgerald et al. [@CR15]; Geyer et al. [@CR21]; Gold et al. [@CR22]; Gould et al. [@CR25]; Kulkarni and Dandiya [@CR40]; Meliska and Loke [@CR44]; Paulus and Geyer [@CR48]; Sessions et al. [@CR61]). We developed the behavioral pattern monitor (BPM) for use in rats (Geyer et al. [@CR21]; Paulus and Geyer [@CR49]) and mice (Risbrough et al. [@CR55]). The BPM combines aspects of each of these testing chambers, enabling quantitative multivariate assessments of activity, exploration, and locomotor patterns simultaneously. The BPM has proven to be effective in differentiating between diverse stimulants including amphetamine, apomorphine, caffeine, 3,4-methylenedioxy-*N*-methylamphetamine, nicotine, phencyclidine, and scopolamine (Geyer and Paulus [@CR20]; Geyer et al. [@CR21]; Paulus and Geyer [@CR49]). The same principles of multivariate assessment used to differentiate stimulants in the BPM have recently been applied to quantifying the behavior of psychiatric inpatients in a human BPM, the development and conception of which is described elsewhere (Young et al. [@CR73]). As predicted, manic BD patients exhibit increased activity as measured by counts, distance traveled, and acceleration. BD patients also exhibit significantly more specific exploratory behavior than healthy comparison subjects as measured by object interactions. Moreover, the structure of the locomotor paths taken by BD patients differed from comparison subjects, with BD patients exhibiting reduced spatial *d*, indicative of distance covering as opposed to localized meandering exploration (Perry et al. [@CR52]). Importantly, the exploratory profile of BD manic patients also differed considerably from that of schizophrenia patients, suggesting differing behavioral profiles dependent upon psychotic disorder (Perry et al. [@CR52]). Hence, there exists a detailed quantitative assessment of behavior selective to BD inpatients, which animal models specific to BD mania should therefore also exhibit.

As discussed elsewhere (Geyer and Markou [@CR19]), the identification of an animal model of a neuropsychiatric disorder can benefit both by comparisons with quantified behavioral characteristics seen in the disorder and by reference to the neural substrates that are hypothesized to underlie the abnormal behavior. A dysregulation of dopaminergic homeostasis may contribute to the BD mania profile (Manji et al. [@CR42]; Vawter et al. [@CR68]; Young et al. [@CR70]). Abnormal expression of the dopamine transporter (DAT) has been implicated in the neuropathophysiology of BD through genetic linkage studies (Greenwood et al. [@CR26], [@CR27]; Kelsoe et al. [@CR35]), with the functional consequences of an observed DAT mutation leading to reduced cell surface DAT expression (Horschitz et al. [@CR32]). Amphetamine, which inhibits the DAT and other monoamine transporters (Han and Gu [@CR29]; Rothman and Baumann [@CR57]), is one of the most common animal models of BD in mice (Arban et al. [@CR1]; Gould et al. [@CR25]), rats (Cappeliez and Moore [@CR5]; Frey et al. [@CR17]; Shaldivin et al. [@CR62]), and humans (Asghar et al. [@CR2]; Silverstone et al. [@CR63]). Despite the prevalent use of amphetamine as a model of BD, however, there has been limited success in developing therapies specifically for BD. Indeed, most current treatments were developed originally for other disorders and/or resulted from serendipitous observations (Cryan and Slattery [@CR8]; Gould and Einat [@CR23]). This poor treatment development rate may be due in part to the lack of pharmacological selectivity of the commonly used model, amphetamine. Amphetamine exhibits approximately a 5- to 9-fold greater affinity for the norepinephrine transporter (NET) than the DAT, with some efficacy at blocking serotonergic transporters also (Han and Gu [@CR29]). DAT knockdown (KD) mice on a 129/S background strain exhibit a selective 90% reduction in DAT expression (Zhuang et al. [@CR77]). Recently, we demonstrated that DAT KD mice exhibit a phenotype in the mouse BPM that mimicked the profile of manic BD patients, increased activity and specific exploration with reduced spatial *d* representative of greater distance covering behavior. In preliminary studies, acute administration of 2.5 mg/kg amphetamine to C57BL/6J mice did not reproduce the manic BD phenotype as reduced specific exploration was observed (Perry et al. [@CR52]). Acute administration of the DAT selective inhibitor GBR 12909 (Heikkila and Manzino [@CR30]) at 16 mg/kg, however, did produce a behavioral profile in C57BL/6J mice that was consistent with both BD mania patients and DAT KD mice (Perry et al. [@CR52]). Thus, it appeared that GBR 12909 but not the "gold standard" mania model---amphetamine treatment---reproduced the BD mania exploratory phenotype in C57BL/6J mice.

Based on these initial findings, the present studies were designed to compare the full dose--response functions for the effects of amphetamine and GBR 12909 on exploratory behavior in C57BL/6J mice assessed in the BPM. We also examine the time course of the effects of GBR 12909 over 3 h. Finally, we examined the cross-strain consistency of effects of GBR 12909 by testing the same dose--response curve in 129/SJ mice in order to compare the drug-induced profile with the phenotype observed in DAT KD mice. We hypothesized that selective DAT inhibition produces a "mania-like" phenotype in mice that is independent of strain, long lasting, and not reproduced by any tested dose of amphetamine.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

To assess the effects of amphetamine and GBR 12909, male C57BL/6J and 129/SvJ mice (20--40 g) were obtained from Jackson Laboratories and tested at approximately 4 months old. All mice were housed in groups of maximum four per cage with a reversed day--night cycle (lights on at 8.00 [p.m.]{.smallcaps}, off at 8.00 [a.m.]{.smallcaps}) at the University of California, San Diego (UCSD) vivarium. The animals had unlimited access to water and food (Harlan, Madison, WI, USA) except during testing. Before testing, all mice were brought to the testing room covered against exposure to light for an acclimation period of at least 60 min. Testing occurred between 9.00 [a.m.]{.smallcaps} and 6.00 [p.m]{.smallcaps}. All of the behavioral testing procedures were approved by the UCSD Institutional Animal Care and Use Committee. All mice were maintained in an animal facility that meets all federal and state requirements for animal care and was approved by the American Association for Accreditation of Laboratory Animal Care.

Drugs {#Sec4}
-----

*d*-Amphetamine sulfate (Sigma, St. Louis, MO, USA) was dissolved in saline and was administered with a 5-ml/kg injection volume. GBR 12909 dihydrochloride (Sigma, St. Louis, MO, USA) was dissolved in saline after sonicating for 2--4 h at 40°C. Due to the poor solubility of GBR 12909 in saline, the injection volume was increased to 10 ml/kg. Free-base drug weights were used in all drug calculations. All drugs were administered by intraperitoneal injection immediately prior to the mice being placed in the testing chambers and data recording initiated. Saline (0.9%) was used as vehicle in each experiment. Drug doses were based on previous studies demonstrating increased activity and exploration following amphetamine (Gould et al. [@CR25], [@CR24]; Arban et al. [@CR1]) and GBR 12909 treatment (van den Buuse and de Jong [@CR67]; Zalcman [@CR76]).

Mouse behavioral pattern monitor {#Sec5}
--------------------------------

Spontaneous locomotor and exploratory behavior was examined in ten mouse BPM chambers as described previously (Risbrough et al. [@CR55]). In brief, a single chamber consists of a 30.5 × 61 × 38-cm area, with a Plexiglas hole board floor that was equipped with floor holes in the front, middle, and rear parts of the floor and eight wall holes (three along each side of the long walls and two holes in the front and back walls). Each hole is equipped with an infrared photobeam so holepoking behavior can be detected. The chamber is illuminated from a single light source above the arena (producing 350 lux in the center and 92 lux in the four corners). The location of the mouse is obtained from a grid of 12 × 24 infrared photobeams 1 cm above the floor (2.5 cm apart along the length and the width of the chamber; 24_12 *X*--*Y* array), recording the location of the mouse every 0.1 s, with its position defined across nine unequal regions (four corners, four walls and center; Geyer et al. [@CR21]). Rearing behavior is detected by an array of 16 infrared photobeams placed 2.5 cm above the floor and aligned with the long axis of the chamber. At the start of each test session, mice were placed in the bottom left-hand corner of the chamber, facing the corner, and the test session started immediately. The primary measures of interest were activity (transitions---movement across the defined regions), exploratory behavior (holepoking and rearing), and locomotor pattern (spatial *d*). Spatial *d* quantifies the geometrical structure of the locomotor path, where a value of 2 represents highly circumscribed small-scale movements, while 1 represents straight-line distance-covering movements. To quantify spatial *d*, the path length of the animal is separated into micro-events based on successive (*x*,*y*) coordinates to which different measuring resolutions (*k*) are applied. Using a large *k* corresponds to a more global depiction of movement while smaller *k* values provide quantification of local events. Fitting a slope using a least-squares straight-line approximation between the logarithm of the values generated by these *k* ranges provides the value for the spatial scaling exponent *d* (Paulus and Geyer [@CR47]).

Experiment 1: dose--response study on the effects of amphetamine on C57BL/6J mice in the mouse BPM {#Sec6}
--------------------------------------------------------------------------------------------------

This study was conducted to determine a dose--response effect of amphetamine in C57BL/6J male mice administered vehicle (*n* = 6) or amphetamine at 0.5 (*n* = 7), 1.25 (*n* = 7), 2.5 (*n* = 7), 5 (*n* = 7), or 10 (*n* = 7) mg/kg. These mice had previously been exposed to the mouse BPM as well as an alpha 7 nicotinic acetylcholine receptor agonist and antagonists on two previous occasions, with \>8 weeks washout period between studies. Some data from the mice treated with 2.5 mg/kg amphetamine were presented previously in Perry et al. ([@CR52]). The locomotor and behavioral activity of the mice was assessed for 60 min in the BPM.

Experiment 2: dose--response curve of GBR 12909---effects on C57BL/6J mice in the mouse BPM {#Sec7}
-------------------------------------------------------------------------------------------

To establish the behavioral effects of GBR 12909 in the mouse BPM, a dose--response study was performed on C57BL/6J mice over 60 min. Eighty male C57BL/6J mice were assessed in the BPM after acute administration of vehicle (*n* = 14) or GBR 12909 at 2.85 (*n* = 14), 5 (*n* = 13), 9 (*n* = 13), 16 (*n* = 13), or 28.5 mg/kg (*n* = 13). These mice had previously been exposed to the mouse BPM for characterization purposes one time over 10 weeks previously to current testing and were drug naïve. Some data from the mice treated with 16 mg/kg GBR 12909 were presented previously in Perry et al. ([@CR52]).

Experiment 3: dose--response curve of GBR 12909---effects on 129/SvJ mice in the mouse BPM {#Sec8}
------------------------------------------------------------------------------------------

To assess putative strain-independent effects of GBR-12909 and to compare them with the phenotype of DAT-deficient mice on a mixed 129/SvJ-C57BL/6 background, a dose--response study was performed in 129/SvJ mice over 60 min. A total of 60 experimentally naïve mice were treated acutely immediately prior to testing in the mouse BPM with vehicle (*n* = 9) or GBR 12909 at 5 (*n* = 8), 9 (*n* = 8), 10.9 (*n* = 9), 13.2 (*n* = 9), 16 (*n* = 9), or 28.5 mg/kg (*n* = 8).

Experiment 4: duration of action of GBR 12909 in C57BL/6J mice in the mouse BPM {#Sec9}
-------------------------------------------------------------------------------

To determine the duration of action of GBR 12909, a dose--response study was performed in C57BL/6J mice prior to a 3-h assessment of exploratory behavior in the mouse BPM. Experimentally, naïve mice were treated acutely with vehicle (*n* = 8) or 9 (*n* = 8), 16 (*n* = 8), or 28.5 mg/kg (*n* = 8) GBR 12909.

Statistics {#Sec10}
----------

The data from each experiment were analyzed using a mixed analysis of variance, with treatment as a between-subject variable and time as a within-subject variable. Significant main effects were analyzed using Tukey's post hoc analyses. The data were analyzed in 10- or 30-min time bins using the Biomedical Data Programs statistical software (Statistical Solutions Inc., Saugus, MA, USA). The alpha level was set to 0.05.

Results {#Sec11}
=======

Experiment 1: amphetamine dose--response study {#Sec12}
----------------------------------------------

A dose--response curve of amphetamine was generated in male C57BL/6J mice to assess the efficacy of amphetamine administration as a pharmacological model of bipolar disorder mania.

**Locomotor activity** A significant drug × time interaction was observed for transitions (*F*(25, 170) = 6.15, *p* \< 0.0001; Fig. [1a](#Fig1){ref-type="fig"}), distance traveled (*F*(25, 170) = 5.84, *p* \< 0.0001), and center entries (*F*(25, 170) = 3.31, *p* \< 0.0001). Tukey's post hoc analysis revealed that mice treated with 5 mg/kg amphetamine exhibited significantly more transitions relative to vehicle (*p* \< 0.05) at time period 1. Mice administered 2.5 mg/kg amphetamine exhibited significantly more transitions than vehicle-treated animals (*p* \< 0.05) in time periods 2, 3, 4, 5, and 6, while mice administered 10 mg/kg amphetamine exhibited significantly lower transitions in the same time periods (*p* \< 0.05). A similar pattern was observed in distance traveled, with mice given 5 mg/kg amphetamine covering significantly greater distance than vehicle-treated mice in time periods 1 and 2 only (*p* \< 0.05), while mice administered 2.5 mg/kg amphetamine exhibited greater distance traveled in every time period (*p* \< 0.05). Mice administered 10 mg/kg amphetamine did not exhibit reduced distance traveled in any time period, likely due to floor effects (*p* \> 0.05), but did exhibit lower center entries compared to vehicle control mice (*p* \< 0.05) in time periods 2 and 5. Fig. 1Effects of amphetamine on exploratory behavior in C57BL/6J mice in the mouse BPM. The nonselective NET and DAT inhibitor amphetamine was administered to mice at various doses prior to their exploration in the mouse BPM. Exploratory behavior was measured as activity levels---transitions (**a**), specific exploration---holepokes (**b**) and rearing (**c**), as well as locomotor pattern---spatial *d* (**d**). An inverted U-shaped dose--response was observed for amphetamine effects on activity where a low dose (2.5 mg/kg) increased activity levels while higher dose (10 mg/kg) lowered activity levels (**a**). The only effect of amphetamine on specific exploration, however, was to reduce holepoking at all but the lowest dose (**b**), with no effect on rearing (**c**). Consistent with activity levels, there was a separation of effects between a low (2.5 mg/kg) and high (10 mg/kg) dose, with some reduction in spatial *d* at low and increased spatial *d* at high doses (**d**). Data presented as mean ± SEM. \**p* \< 0.05 when compared to vehicle control

**Exploration** Significant main effects of drug were observed for holepoking behavior (*F*(5, 34) = 11.03, *p* \< 0.0001; Fig. [1b](#Fig1){ref-type="fig"}) and time spent in the center (*F*(5, 34) = 2.64, *p* \< 0.05), while a significant drug × time interaction was observed for rearings (*F*(25, 170) = 3.12, *p* \< 0.0001; Fig. [1c](#Fig1){ref-type="fig"}). Post hoc analysis revealed a dose--response effect of amphetamine significantly lowering holepoking behavior, observed in mice administered 2.5, 5.0, and 10.0 mg/kg when compared to vehicle (*p* \< 0.05), with a trend to lower holepoking behavior observed in 1.25 mg/kg amphetamine-treated mice (*p* \< 0.1). Post hoc analyses did not reveal any significant effect of any dose compared to vehicle in center entries or rearings at any time period (*p* \> 0.05).

**Locomotor pattern** A significant drug × time interaction was observed for spatial *d* (*F*(25, 170) = 4.56, *p* \< 0.0001; Fig. [1d](#Fig1){ref-type="fig"}). Post hoc analyses indicated that mice administered 10 mg/kg amphetamine displayed higher spatial *d* at time periods 3, 4, and 5 when compared to vehicle-treated mice (*p* \< 0.05), further supporting a stereotypic effect at this dose. Mice administered 2.5 mg/kg amphetamine, however, displayed lower spatial *d* when compared to vehicle controls (*p* \< 0.05) although only at time period 1.

Experiment 2: dose--response curve of GBR 12909---effects on C57BL/6J mice in the mouse BPM {#Sec13}
-------------------------------------------------------------------------------------------

A dose--response study was performed with the selective DAT inhibitor GBR 12909 (vehicle, 2.85, 5, 9, 16, and 28.5 mg/kg) in C57BL/6J mice.

**Locomotor activity** Significant time × drug interactions were found for transitions (*F*(25, 340) = 10.22, *p* \< 0.0001; Fig. [2a](#Fig2){ref-type="fig"}), distance traveled (*F*(25, 340) = 11.06, *p* \< 0.0001), and center entries (*F*(25, 340) = 2.84, *p* \< 0.0001). Tukey's post hoc analyses for transitions revealed that mice administered 16 and 28.5 mg/kg of GBR 12909 exhibited higher levels of transitions (*p* \< 0.05) than vehicle-treated mice in time periods 2 (16 mg/kg only), 3, 4, 5, and 6. The analyses for distance traveled revealed that mice administered 16 mg/kg GBR 12909 exhibited higher levels of transitions (*p* \< 0.05) than vehicle-treated mice in all time periods, while mice administered 28.5 mg/kg GBR 12909 differed from vehicle (*p* \< 0.05) in time periods 2, 3, 4, 5, and 6. For center entries, post hoc analyses revealed that mice administered 16 mg/kg GBR 12909 displayed higher levels of center entries than mice administered vehicle in time periods 2, 3, 4, 5, and 6 (*p* \< 0.05). Fig. 2Effects of GBR 12909 on exploratory behavior in C57BL/6J mice in the mouse BPM. Mice were administered various doses of the selective DAT inhibitor GBR 12909 prior to the assessment of their exploration in the mouse BPM. Exploration was measured in the BPM for activity levels---transitions (**a**), exploration---holepoking (**b**) and rearing (**c**), as well as locomotor patterns---spatial *d* (**d**). GBR 12909 increased activity at the highest (16 and 28.5 mg/kg) doses tested (**a**). The effects of GBR 12909 on exploration differed by dose and measure---the highest dose lowered holepoking (**b**) while the second highest dose increased rearing (**c**). Data presented as mean ± SEM. \**p* \< 0.05 when compared to vehicle administered control mice

**Exploratory behavior** Significant time × drug interactions were observed for holepoking (*F*(25, 340) = 1.63, *p* \< 0.05; Fig. [2b](#Fig2){ref-type="fig"}) and rearing (*F*(25, 340) = 6.74, *p* \< 0.0001; Fig. [2c](#Fig2){ref-type="fig"}). A nonsignificant trend effect of drug was observed for center duration (*F*(5, 68) = 2.32, *p* = 0.0521) but no significant time × drug interaction. Post hoc analyses for holepokes revealed that during time periods 2 and 3, mice administered 28.5 mg/kg of GBR 12909 showed lower levels of holepoking behavior than mice administered vehicle (*p* \< 0.05). For rearing, mice administered 16 mg/kg GBR 12909 reared more than vehicle-treated mice in time periods 3, 4, 5, and 6 (*p* \< 0.05).

**Locomotor patterns** A significant time × drug interaction was observed for spatial *d* (*F*(25, 340) = 3.61, *p* \< 0.0001; Fig. [2d](#Fig2){ref-type="fig"}). Post hoc analyses revealed that mice administered 16 and 28.5 mg/kg GBR 12909 showed lower values of spatial *d* than mice administered vehicle in time periods 3, 4, 5, and 6 (*p* \< 0.05). Mice administered 5 mg/kg had significantly lower levels of spatial *d* when compared to vehicle-treated mice in time periods 5 and 6 (*p* \< 0.05), while mice administered 9 mg/kg GBR 12909 exhibited lower spatial *d* values in time period 5 compared to vehicle (*p* \< 0.05).

Experiment 3: dose--response curve of GBR 12909---effects on 129/SvJ mice in the mouse BPM {#Sec14}
------------------------------------------------------------------------------------------

A dose--response study was performed with the selective DAT inhibitor GBR 12909 (vehicle, 5, 9, 10.9, 13.2, 16, and 28.5 mg/kg) in 129/SvJ mice. We hypothesized that the effects of GBR 12909 would be similar to those seen in C57BL/6J mice and to the phenotype of the DAT-deficient mutant mice tested in the mouse BPM.

**Locomotor activity** Significant main effects of drug were found for transitions (*F*(6, 53) = 4.99, *p* \< 0.0005; Fig. [3a](#Fig3){ref-type="fig"}), distance traveled (*F*(6, 53) = 6.30, *p* \< 0.0001), and center entries (*F*(6, 53) = 2.54, *p* \< 0.05). Furthermore, time × drug interactions were observed for transitions (*F*(30, 265) = 6.49, *p* \< 0.0001), distance traveled (*F*(30, 265) = 6.1, *p* \< 0.0001), and center entries (*F*(30, 265) = 2.6, *p* \< 0.0001). Tukey's post hoc analyses revealed that 16 mg/kg GBR 12909 increased transitions and distance traveled when compared with saline for time periods 2--6 and increased center entries for time periods 3--6 (*p* \< 0.05). GBR 12909 at 28.5 mg/kg increased transitions and distance traveled when compared to saline at time periods 2--6 (*p* \< 0.05, although *p* \< 0.1 for transitions in time period 1) and increased center entries in time periods 3 and 6 only. Increases in transitions and distance traveled were also observed for 13.2 and 10.9 mg/kg GBR 12909 at time periods 3--6 (*p* \< 0.05), while 9 mg/kg increased transitions and distance traveled in time periods 5 and 6 only (*p* \< 0.05). GBR 12909 at 10.9 mg/kg also increased center entries when compared to saline in time periods 5 and 6 (*p* \< 0.05). Fig. 3Effects of GBR 12909 on exploratory behavior in 129/SvJ mice in the mouse BPM. Mice (129/SvJ) were administered various doses (5, 9, 10.9, 13.2, 16, and 28.5 mg/kg) of the selective DAT inhibitor GBR 12909 immediately prior to the assessment of their exploration in the mouse BPM. Exploration was measured in the BPM for activity levels---transitions (**a**), exploration---holepoking (**b**) and rearing (**c**), as well as locomotor patterns---spatial *d* (**d**). GBR 12909 increased activity at various doses tested, only 16 and 28.5 mg/kg initially but also 9, 10.9, and 13.2 mg/kg by the end of testing (**a**). The effects of GBR 12909 on exploration were similar for the two measures, with 16 and 28.5 mg/kg increasing holepoking (**b**) and rearing (**c**) toward the end of the test session. Doses of GBR 12909 larger than 10.9 mg/kg also lowered spatial *d*, although this effect was seen predominantly between 10 and 40 min (**d**). Data presented as mean ± SEM. \**p* \< 0.05 when compared to vehicle administered control mice. Scales on the *x*-axes differ from Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} due to differing basal activity levels of C57BL/6J and 129/SvJ mice

**Exploratory behavior** For holepoking (*F*(6, 53) = 2.90, *p* \< 0.05; Fig. [3b](#Fig3){ref-type="fig"}) and rearing (*F*(6, 53) = 2.59, *p* \< 0.05; Fig. [3c](#Fig3){ref-type="fig"}), significant main effects for drug were observed. Also, time × drug interactions were observed for holepoking (*F*(30, 265) = 2.0, *p* \< 0.005) and rearing (*F*(30, 265) = 2.3, *p* \< 0.0005). No significant effects for center duration were found (*p* \> 0.05). Post hoc analyses of significant interactions revealed for rearing that GBR 12909 at 16 and 28.5 mg/kg induced more rearing when compared to saline in time periods 4--6 (*p* \< 0.05). GBR 12909 at 28.5 mg/kg increased holepoking in time periods 5 and 6, while 16 mg/kg increased holepoking at time period 5, compared to saline-treated mice (*p* \< 0.05).

**Locomotor patterns** A significant main effect of drug was observed for spatial *d* (*F*(6, 53) = 2.59, *p* \< 0.05; Fig. [3d](#Fig3){ref-type="fig"}), and a trend toward a drug × time interaction was observed (*F*(30, 265) = 1.5, *p* = 0.06). Post hoc analyses were performed for the interaction to remain consistent with the rest of the study. Post hoc analyses revealed that GBR 12909 lowered the value of spatial *d* for doses 10.9, 16, and 28.5 mg/kg when compared to saline in time periods 2, 3, and 4, while 13.3 mg/kg GBR 12909 reduced spatial *d* in time period 2 only (*p* \< 0.05).

Experiment 4: duration of effect of acute GBR 12909 in C57BL/6J mice in the mouse BPM {#Sec15}
-------------------------------------------------------------------------------------

The duration of effect of GBR 12909 was assessed by administering multiple doses (vehicle, 9, 16, or 28.5 mg/kg) to C57Bl/6J mice immediately prior to their assessment in the mouse BPM for an extended period of time (3 h). We hypothesized that GBR 12909 would exhibit long-lasting effects on exploratory behavior.

**Locomotor activity** Significant main effects of drug were observed for transitions (*F*(3, 32) = 20.4, *p* \< 0.0001; Fig. [4a](#Fig4){ref-type="fig"}), distance traveled (*F*(3, 32) = 21.4, *p* \< 0.0001), and center entries (*F*(3, 32) = 3.2, *p* \< 0.05). Moreover, time × drug interactions were observed for transitions (*F*(15, 160) = 3.7, *p* \< 0.0001), distance traveled (*F*(15, 160) = 4.4, *p* \< 0.0001), and center entries (*F*(15, 160) = 2.0, *p* \< 0.05). Tukey's post hoc analyses revealed GBR 12909 at all three doses increased transitions and distance traveled at all six 30-min time intervals (*p* \< 0.05), except for 9 mg/kg at time point 1 (*p* \> 0.05). Increased center entries were observed following 9 mg/kg GBR 12909 at time periods 2, 2, 5, and 6, 16 mg/kg at time periods 3 and 6, and 28.5 mg/kg at time period 3 (*p* \< 0.05). Fig. 4Time course of the effects of GBR 12909 on exploratory behavior in C57BL/6J mice in the mouse BPM. Mice were administered the selective DAT inhibitor GBR 12909 at various doses (9, 16, and 28.5 mg/kg) immediately prior a 3-h assessment of their exploration in the mouse BPM. Activity levels---transitions (**a**), exploration---holepoking (**b**) and rearing (**c**), as well as locomotor patterns---spatial *d* (**d**) were all measured. GBR 12909 increased activity at various doses tested, only 16 and 28.5 mg/kg initially but also 9 mg/kg throughout the 3-h period (**a**). Despite an initial drop in holepoking, GBR 12909 at 16 mg/kg consistently increased holepoking (**b**) and rearing (**c**). GBR 12909 at 16 mg/kg also consistently lowered spatial *d* (**d**), with some modest effects at 9 and 28.5 mg/kg as well. Data presented as mean ± SEM. \**p* \< 0.05 when compared to vehicle administered control mice

**Exploratory behavior** No significant main effects of drug were observed for holepoking (Fig. [4b](#Fig4){ref-type="fig"}) or center duration, but there was a main effect of drug on rearing (*F*(3, 32) = 5.0, *p* \< 0.01; Fig. [4c](#Fig4){ref-type="fig"}). Time × drug interactions were observed, however, for holepoking (*F*(15, 160) = 7.1, *p* \< 0.0001), rearing (*F*(15, 160) = 6.0, *p* \< 0.0001), and center entries (*F*(15, 160) = 3.1, *p* \< 0.0005). Post hoc analyses of significant interactions revealed that 16 mg/kg GBR 12909 increased rearing at 30-min time intervals 3--6, while 9 mg/kg increased rearing at time periods 3, 5, and 6 and 28.5 mg/kg increased rearing at time periods 5 and 6 only (*p* \< 0.05). While 16 and 28.5 mg/kg initially decreased poking at time period 1 (*p* \< 0.05), 16 mg/kg increased poking at time periods 5 and 6, while 9 mg/kg increased poking in the fifth time period (*p* \< 0.05). Increased center duration was observed for 9 mg/kg at time periods 5 and 6 (*p* \< 0.05).

**Locomotor patterns** A significant main effect of drug was observed for spatial *d* (*F*(3, 32) = 6.1, *p* \< 0.005; Fig. [4d](#Fig4){ref-type="fig"}). A time × drug interaction was also observed for spatial *d* (*F*(15, 160) = 12.4, *p* \< 0.005). Post hoc analyses revealed differing effects of drug dose over the 3-h period. GBR 12909 at 16 mg/kg reduced spatial *d* relative to saline at time periods 1, 3, 4, and 5, while 28.5 mg/kg reduced spatial *d* only at time periods 1, 3, and 4 and 9 mg/kg reduced spatial *d* only at time periods 3 and 4 (*p* \< 0.05).

Discussion {#Sec16}
==========

We investigated the predictive validity of two animal models of quantified hyperexploration in BD mania. These treatment models included the "gold standard" mixed NET/DAT inhibitor amphetamine and the selective DAT inhibitor GBR 12909. Amphetamine administration induced hyperactivity, as well as reduced spatial *d* at low doses, consistent with BD mania patients, with the opposite effect at high doses. Amphetamine reduced specific exploratory activity at multiple doses, however (Fig. [1](#Fig1){ref-type="fig"}), in contrast to manic BD patients in the human BPM (Perry et al. [@CR52]). Mice administered 16 mg/kg GBR 12909, irrespective of background strain, consistently exhibited increased activity, reduced spatial *d*, and increased exploratory behavior (Fig. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, and [4](#Fig4){ref-type="fig"}). Thus, the phenotype produced by selectively inhibiting DAT function in the mouse BPM was consistent with the behavior of BD patients in the human BPM.

Amphetamine is a relatively nonselective monoamine reuptake inhibitor, being most potent at the NET with 6--10-fold less efficacy at DAT in rats, mice, and humans (Han and Gu [@CR29]; Holmes and Rutledge [@CR31]). Although amphetamine treatment has been a popular model with which to assess mania (Einat [@CR12]; Frey et al. [@CR17]; Gould et al. [@CR25]; Silverstone et al. [@CR63]), the main phenotype of BD modeled has been that of increased motor activity. While lithium has been shown to reduce amphetamine-induced hyperactivity in four out of 12 strains of mice, this effect was observed in doses that also reduced activity levels (Gould et al. [@CR24]). Hence, it remains unclear whether lithium specifically ameliorated amphetamine-induced hyperactivity. Here, we demonstrate that while 2.5 mg/kg amphetamine produced hyperactivity, the higher dose of 10 mg/kg significantly reduced activity levels presumably due to the induction of competing stereotypies (Fig. [1a](#Fig1){ref-type="fig"}). Recent studies providing quantitative assessments of exploratory behavior in manic BD patients have revealed a more complex phenotype, with locomotor hyperactivity being accompanied by increased specific exploratory interactions and reduced spatial *d* compared to healthy comparison subjects (Perry et al. [@CR52]). While amphetamine administration lowered spatial *d* at certain doses, it also significantly increased spatial *d* at the highest dose. The reported effects of amphetamine on specific exploratory behavior have been contradictory, with no effect (Kokkinidis and Zacharko [@CR39]), reduced holepoking/rearing (File and Wardill [@CR13]; Lister and File [@CR41]), or increased rearing (Gulley et al. [@CR28]; Kim et al. [@CR36]) all being reported. In the present study conducted in the mouse BPM---a direct analog of the human BPM in which the exploratory behavior of BD patients has been characterized---amphetamine reduced exploratory behavior in contrast to the behavior of manic BD patients (Fig. [1b](#Fig1){ref-type="fig"}; Perry et al. [@CR52]). In fact, amphetamine induced a dose-related reduction in specific exploratory activity in the mouse BPM as measured by hole interactions. The combined effect of amphetamine on both NET and DAT is likely to underlie its effect of reducing specific exploration. Manipulation of the norepinephrine system affects exploratory activity (Flicker and Geyer [@CR16]; Kitchigina et al. [@CR37]; Mansour et al. [@CR43]; Sara et al. [@CR60]), with increased norepinephrine in the synaptic cleft---which occurs following NET inhibition---having been demonstrated to reduce exploratory behavior of rats in the holeboard task (Sara et al. [@CR60]). An alternative explanation is that reduced specific exploration following amphetamine administration was a result of the development of stereotypic behavior. Although the reduction in activity after administration of amphetamine at 10 mg/kg was likely due to competing stereotypies, which also resulted in increased spatial *d* (see Paulus and Geyer [@CR47]), such stereotypy is unlikely to have interfered with specific exploration at low doses (1.25 and 2.5 mg/kg). In fact, stereotypy does not appear to affect amphetamine-induced increases in locomotor activity at doses as low as 2 mg/kg in C57BL/6 mice (Yates et al. [@CR69]). Thus, given that amphetamine inhibits NET and that selective NET inhibition can reduce specific exploration, these data support concerns raised regarding the validity for the amphetamine treatment model of BD in humans (Silverstone et al. [@CR63]), rats (Cappeliez and Moore [@CR5]; Frey et al. [@CR17]), and mice (Arban et al. [@CR1]; Gould et al. [@CR25]). There has been recent interest in the use of the combined amphetamine/chlordiazepoxide treatment-induced hyperactivity as a model of mania, first described in 1966 (Rushton and Steinberg [@CR59]). Although not assessed in the present study and knowledge of the effects of this model on spatial *d* and specific exploration are unknown, there is some evidence that low doses of antimanic agents can attenuate this combined model-induced hyperactivity which do not affect activity alone (Arban et al. [@CR1]; Dencker et al. [@CR9]; Vale and Ratcliffe [@CR66]). There is evidence, however, that the observed attenuation of hyperactivity may not be as a result of blockade of the combined drug effects on activity but a chlordiazepoxide-induced potentiation of the hypolocomotor effects of antimanic agents (Arban et al. [@CR1]; Kelly et al. [@CR34]). Thus, it has been suggested that this model may not prove useful in a drug discovery process due to interpretive difficulties (Kelly et al. [@CR34]).

We have demonstrated that more selective inhibition of the DAT through either genetic or pharmacological manipulation did, however, increase exploration in mice as well as inducing hyperactivity and reducing spatial *d* (Perry et al. [@CR52]). Administration of GBR 12909 induced locomotor hyperactivity consistent with amphetamine (Fig. [5](#Fig5){ref-type="fig"}). GBR 12909 at 16 mg/kg in two background strains led to a hyperactive phenotype that differed from amphetamine but was consistent with previous reports (Kliethermes and Crabbe [@CR38]; Mitchell et al. [@CR46]; van den Buuse and de Jong [@CR67]). Thus, 16 mg/kg GBR 12909 also reduced spatial *d* and increased specific exploration (rearing), a phenotype consistent with that of BD patients in the human BPM (Perry et al. [@CR52]). The observed increase in exploration is in concurrence (van den Buuse and de Jong [@CR67]; Zalcman [@CR76]) and in contrast (Kliethermes and Crabbe [@CR38]) with previous reports, although the latter study used WSC rather than C57BL/6J mice as in the present studies and did not examine doses between 10 and 20 mg/kg, where the greatest effects were observed in the present studies. Thus, the data presented here support the selectivity of effects of 16 mg/kg GBR 12909, with lower doses being less effective and higher doses producing effects consistent with amphetamine. The reduction in specific exploration observed with the highest dose of GBR 12909 (28.5 mg/kg) is consistent with the hypothesis that both DAT and NET inhibition reduces exploratory behavior, as observed above with amphetamine. Despite greater selectivity for the DAT, GBR 12909 may inhibit the NET at this dose (Heikkila and Manzino [@CR30]). In support of the DAT-selective phenotype, the present DAT inhibition studies corroborate reports of increased activity and reduced spatial *d* in mice with reduced DAT levels (Cagniard et al. [@CR4]; Ralph-Williams et al. [@CR54]; Zhuang et al. [@CR77]), as well as adding to observations of increased hole interactions (Perry et al. [@CR52]). Fig. 5Representative actigrams from each study. The movement patterns of mice from each study are recorded and analyzed. These figures are representative patterns of movements from mice of each study. Patterns are from the 10--20-min time point of testing. As shown, amphetamine (**a**) and GBR 12909 administered (**b**) mice exhibit increased activity levels in the mouse BPM compared to their respective controls. The increased activity also led to more straight distance-covering behavior (lower spatial *d*) in these mice

While DAT KD mice exhibited increased holepoking (Perry et al. [@CR52]), GBR 12909 induced increased rearing in C57BL/6J and 129/SvJ mice. Given that GBR 12909 increased holepoking and rearing in 129/SvJ mice and increased holepoking in C57BL/6J mice after 150 min of testing suggests that there is an interaction between GBR 12909 dose and background strain. Previously, strain differences in exploration have been observed in these mice. For example, relative to 129 strains, C57BL/6J mice are notably more active (Paulus et al. [@CR51]) and exhibit baseline differences in these exploratory measures (Rogers et al. [@CR56]; Tang and Sanford [@CR65]). The increased holepoking with time in C57BL/6J mice could also be as a result of the effect of a metabolite of GBR 12909. To our knowledge, the half-life of GBR 12909 has not been studied in mice, however; thus, it is unknown whether GBR 12909 remains active after 150 min, although many studies suggest it has a long half-life in comparison to amphetamine (55 min in mice, 6--9 h in humans; Cho et al. [@CR6]; GBR 12909 equals 48--57 h in humans, Ingwersen et al. [@CR33]; Preti [@CR53]). The present studies demonstrate, however, that by reducing DAT function genetically or pharmacologically resulted in a behavioral profile of increased activity, reduced spatial *d*, and increased specific exploration that mimics that observed in manic BD patients (Perry et al. [@CR52]). Such data may prove useful in guiding future studies investigating the neurobiological basis for BD mania as well as potential treatment options.

Further validation of these models of BD mania is still required, however, such as assessing treatment effects on behavior for example, although given that antimanic treatment does not fully treat BD mania, we would not expect a full reversal of the GBR 12909 phenotype. Further assessment of the cross-species translational validity of the BPM is also required and could include amphetamine administration to healthy patients to ascertain whether the behavioral profile described here following amphetamine treatment in mice would be reproduced in man. This comparison may be particularly relevant given the differences in space availability to test subject ratio for the human and mouse BPMs. Evidence for the suitability of GBR 12909 treatment modeling mania could also be derived from other aspects of behavior relating to BD as defined by the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* rating scale, such as aggression, hedonism, hypersexuality, distractibility, reduced sleep (Einat [@CR11]), inattention (Young et al. [@CR71], [@CR74]), working memory (Young et al. [@CR72]), and executive functioning. For example, given the fact that GBR 12909 produces a long-lasting effect on mice in the BPM, it would be feasible to assess its effects on the cognitive performance of mice in tasks that last several hours, such as the attentional set-shifting task (Young et al. [@CR75]). Other relevant behaviors include reduced sleep, increased reward values, lower anxiety, and hyperactive behavior seen in BD and also observed in mice carrying a mutation in the Clock gene (Roybal et al. [@CR58]). Since chronic administration of the mood stabilizer lithium attenuated many of these phenotypes, these mutants may also represent a viable animal model of BD. It would be interesting to assess the specific exploratory phenotype of these mice in the mouse BPM, given the quantified exploratory phenotype we have observed in manic BD patients (Perry et al. [@CR52]). Future studies could also investigate the hypothesis that it is the combined effect of amphetamine on DAT and NET that produces a behavioral profile similar, but not fully consistent with manic BD patients. This question could be investigated by combining low-dose GBR 12909 treatment with a selective NET inhibitor such as atomoxetine. Irrespective of future studies, however, the data presented here still provide the first animal model of BD mania that is based on the quantification of exploratory activity in these patients, thus perhaps providing a more precise approach to develop novel therapeutics.
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